Document:

Exhibit
4.14

 

NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND
THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN
SECURED BY SUCH SECURITIES.

 

COMMON
STOCK PURCHASE WARRANT

 

Nutralife Biosciences, Inc.

 

	Warrant
    Shares: 800,000	Issue
    Date: January 11, 2021

 

THIS COMMON
STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Gregory Ross (the “Holder”) is
entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or
after the Issue Date as set forth above (the “Issue Date”) and on or prior to 5:00 p.m. (New York City time) on the
third anniversary of the Issue Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from
Nutralife Biosciences, Inc., a Florida corporation (the “Company”), up to the number of shares set forth above (as
subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise
Price, as defined in Section 2(b), subject to adjustment as set forth herein.

 

Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Subscription Agreement (the
“Agreement”), dated January 11, 2021, among the Company and the Holder. This Warrant is subject to the terms and conditions
of the Agreement and, in the event of a conflict between the Agreement and this Warrant, the terms and conditions of this Warrant shall
control. In addition, for purposes herein:

 

(a)
The Company and the Holder may be referred to herein individually as a “Party” and collectively as the “Parties”.

 

(b)
“Affiliate” means, with respect to a specified Person, any other Person that directly or indirectly Controls, is Controlled
by or is under common Control with, the specified Person.

 

(c)
“Business Day” means any day except Saturday, Sunday and any legal holiday or a day on which banking institutions
in Florida generally are authorized or required by Law or other governmental actions to close.

 

    	 	 	 

    	 

    

 

(d)
“Control” means (a) the possession, directly or indirectly, of the power to vote 10% or more of the securities or
other equity interests of a Person having ordinary voting power, (b) the possession, directly or indirectly, of the power to direct
or cause the direction of the management and policies of a Person, by contractor otherwise, or (c) being a director, officer,
executor, trustee or fiduciary (or their equivalents) of a Person or a Person that controls such Person.

 

(e)
“Person” means a natural person, a corporation, a limited liability company, a partnership, an association, a trust
or any other entity or organization, including a government or political subdivision or any agency or instrumentality thereof.

 

(f)
“Transfer Agent” means the Company’s transfer agent for the Common Stock as in place from time to time.

 

Section 2. Exercise.

 

(a)
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Issue Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile
copy or PDF copy submitted by e-mail with return receipt requested (or e-mail attachment to an e-mail with return receipt requested)
of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”). Within the earlier of (i) two (2)
Trading Days (as defined bellow) and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in
Section 2(f)(i)) following the date of exercise as aforesaid, the Holder shall deliver to the Company the aggregate Exercise Price
for the shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States
bank unless the cashless exercise procedure specified in Section 2(c) is specified in the applicable Notice of Exercise. No ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice
of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender
this Warrant to the Company until the Holder has exercised the rights to purchase all of the Warrant Shares available hereunder
and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation
together with the final Notice of Exercise as delivered to the Company. Partial exercises of this Warrant resulting in purchases
of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number
of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and
the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases, and the records
of the Company shall be deemed controlling in the absence of manifest error. The Company shall deliver any objection to any Notice
of Exercise within one (1) Business Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant,
acknowledge and agree that, by reason of the provisions of this Section 2(a), following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount
stated on the face hereof.

 

(b)
Exercise Price. The exercise price per share of Common Stock under this Warrant shall be $0.08, subject to adjustment hereunder
(the “Exercise Price”).

 

    	 	2	 

    	 

    

 

(c)
Cashless Exercise. In the event that (1) the Warrant Shares are not registered for resale pursuant to a registration statement
under the Securities Act of 1933, as amended (the “Securities Act”) as of the date of the delivery of a Notice of
Exercise and (2) the Market Price (as defined below) of one share of Common Stock is greater than the Exercise Price in effect
at such time, then this Warrant may also be exercised, in whole or in part, at such time by means of a “cashless exercise”
in which the Holder shall be entitled to receive a number of Warrant Shares computed using the following formula:

 

X
= Y(A-B)

   A

 

Where:

 

	 	X	=	The
    number of Warrant Shares to be issued to Holder
	 	 	 	 
	 	Y	=	the
    number of Warrant Shares that the Holder elects to purchase under this Warrant (at the date of such calculation)
	 	 	 	 
	 	A	=	the
    Market Price (at the date of such calculation)
	 	 	 	 
	 	B	=	the
    Exercise Price (as adjusted to the date of such calculation)

 

(d)
Characteristics. If Warrant Shares are issued in such a cashless exercise, the Parties acknowledge and agree that in accordance
with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised,
and the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company
agrees not to take any position contrary to this Section 2(d).

 

(e)
Market Price. “Market Price” for the Common Stock (or any replacement security pursuant to Section 3(b)) means,
for any security as of any date, the first of the following which shall apply:

 

	 	(i)	the
    dollar volume-weighted average price for such security on the OTC Markets or a United States national securities exchange
    which is the principal market on which such security is then traded (as applicable, the “Trading Market”) during
    the period beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported by Bloomberg L.P.
    through its “HP” function (set to weighted average) or, if the foregoing does not apply, the dollar volume-weighted
    average price of such security in the over-the-counter market on the electronic bulletin board for such security during the
    period beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported by Bloomberg L.P.;
	 	 	 
	 	(ii)	if
    no dollar volume-weighted average price is reported for such security by Bloomberg L.P. for such hours as set forth in Section
    2(e)(i), the average of the highest closing bid price and the lowest closing ask price of any of the market makers for such
    security as reported in the “pink sheets” by OTC Markets Group Inc. (formerly Pink Sheets LLC); and

 

    	 	3	 

    	 

    

 

	 	(iii)	if
    the Market Price cannot be calculated for such security on such date on bases as set forth in Section 2(e)(i) or Section 2(e)(ii),
    the Market Price of such security on such date shall be the fair market value of such security as mutually determined in good
    faith by the Board of Directors of the Company and the Holder after taking into consideration factors they may each deem appropriate.

 

(f)
Mechanics of Exercise.

 

	 	(i)	Delivery
    of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the
    Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The
    Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then
    a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant
    Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without
    volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical
    delivery of a certificate, registered in the Company’s share register in the name of the Holder or its designee, for
    the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder
    in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of
    the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the
    number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise
    (such date, the “Warrant Share Delivery Date”). Upon delivery of the Notice of Exercise, the Holder shall be deemed
    for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has
    been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise
    Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii)
    the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. The Company
    agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding
    and exercisable. As used herein, “Standard Settlement Period” means the standard settlement period, expressed
    in a number of Trading Days, on the Company’s primary Trading Market with respect to the Common Stock as in effect on
    the date of delivery of the Notice of Exercise. For purposes herein, “Trading Day” means any day on which the
    Common Stock (or any replacement security pursuant to Section 3(b)) is traded on the Trading Market or is otherwise reported
    on “pink sheets” by OTC Markets Group Inc. (formerly Pink Sheets LLC) or a similar organization or agency succeeding
    to its functions of reporting prices.

 

    	 	4	 

    	 

    

 

	 	(ii)	Delivery
    of New Warrants Upon Partial Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request
    of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the
    Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant,
    which new Warrant shall in all other respects be identical with this Warrant.
	 	 	 
	 	(iii)	No
    Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
    of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise,
    the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such
    fraction multiplied by the Exercise Price or round up to the next whole share.
	 	 	 
	 	(iv)	Charges,
    Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
    or other incidental expense of the Company in respect of the issuance of such Warrant Shares, all of which taxes and Company
    expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or
    names as may be directed by the Holder; provided, however, that, in the event that Warrant Shares are to be issued in a name
    other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form
    attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient
    to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day
    processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation
    performing similar functions) required for same-day electronic delivery of the Warrant Shares.

 

    	 	5	 

    	 

    

 

(g)
Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and the Holder shall not
have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect
to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s
Affiliates, and any other Person acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons,
“Attribution Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).
For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates
and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect
to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon
(i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates
or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of
the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.
Except as set forth in the preceding sentence, for purposes of this Section 2(g), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged
by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of
the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(g) applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant
is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be
the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the
Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d)
of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(g), in determining the
number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected
in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent
public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the
number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within two Trading
Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number
of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the
Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number
of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number
of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon
exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation
provisions of this Section 2(g), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of
shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise
of this Warrant held by the Holder and the provisions of this Section 2(g) shall continue to apply. Any increase in the Beneficial
Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions
of this Section 2(g) shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this
Section 2(g) to correct this Section 2(g) (or any portion hereof) which may be defective or inconsistent with the intended Beneficial
Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such
limitation. The limitations contained in this Section 2(g) shall apply to a successor holder of this Warrant.

 

    	 	6	 

    	 

    

 

Section 3. Certain Adjustments.

 

(a)
Stock Splits. If any time while this Warrant is outstanding, the Company effects a forward split or reverse split of the
Common Stock, the number of Warrant Shares shall be appropriately adjusted, with any partial resulting Warrant Share being rounded
up to the next nearest whole number and the Exercise Price shall be proportionately adjusted such that the aggregate Exercise
Price payable hereunder shall remain unchanged. By way of example and not limitation, (i) in the event that the Company effects
a two-for-one forward split of the Common Stock, wherein each issued and outstanding share of Common Stock is converted into two
shares of Common Stock, the number of Warrant Shares shall be increased by 100% and the Exercise Price shall be reduced by 50%;
and (ii) in the event that the Company effects a one-for-two reverse split of the Common Stock, wherein each two issued and outstanding
shares of Common Stock are converted into one share of Common Stock, the number of Warrant Shares shall be reduced by 50% and
the Exercise Price shall be increased by 100%.

 

(b)
Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in
one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company
(and all of its Subsidiaries, taken as a whole), directly or indirectly, effects any sale, lease, license, assignment, transfer,
conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any,
direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant
to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property
and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any
compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities,
cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share
purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off,
merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than
50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons
making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement
or other business combination) (each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant,
the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately
prior to the occurrence of such Fundamental Transaction, the number of shares of Common Stock of the successor or acquiring corporation
or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant
is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(g) on the exercise
of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to
apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common
Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in
a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder
shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such
Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not
the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant
in accordance with the provisions of this Section 3(b) pursuant to written agreements in form and substance reasonably satisfactory
to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the
option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written
instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares
of capital stock of such Successor Entity equivalent to the shares of Common Stock acquirable and receivable upon exercise of
this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with
an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative
value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such
number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant
immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance
to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted
for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the “Company”
shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the
obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.

 

    	 	7	 

    	 

    

 

(c)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th
of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding
as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

(d)
Notice to Holder of Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of
this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price
after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the
facts requiring such adjustment.

 

(e)
Voluntary Adjustment By Company. Subject to the rules and regulations of the Trading Market, the Company may at any time
during the term of this Warrant, subject to the prior written consent of the Holder, reduce the then-current Exercise Price to
any amount and for any period of time deemed appropriate by the board of directors of the Company.

 

Section 4. Transfer of Warrant; Legend.

 

(a)
No Transfer. This Warrant may not be transferred by the Holder to any other person or entity without the prior written
approval of the Company, to be given or withheld in the sole discretion of the Company, and any such attempted transfer in violation
of such limitation shall be null and void and of no force or effect.

 

    	 	8	 

    	 

    

 

(b)
Legends. Any legend required by the securities laws of any state to the extent such laws are applicable to the Warrant
Shares represented by the certificate so legended shall be included on any certificates representing the Warrant Shares. Holder
also understands that the Warrant Shares may bear the following or a substantially similar legend:

 

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, NOR REGISTERED
OR QUALIFIED UNDER ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, DELIVERED AFTER SALE, TRANSFERRED,
PLEDGED, OR HYPOTHECATED UNLESS QUALIFIED AND REGISTERED UNDER APPLICABLE STATE AND FEDERAL SECURITIES LAWS OR UNLESS, IN THE
OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY, SUCH QUALIFICATION AND REGISTRATION ARE NOT REQUIRED. ANY TRANSFER
OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS FURTHER SUBJECT TO OTHER RESTRICTIONS, TERMS AND CONDITIONS WHICH ARE NOT
SET FORTH HEREIN.

 

Section 5. Miscellaneous.

 

(a)
No Rights as Stockholder Until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting
rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(f)(i),
except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a “cashless
exercise” pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(f)(i) and Section 2(f)(iii), in no
event shall the Company be required to net cash settle an exercise of this Warrant.

 

(b)
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.

 

(c) Entire
Agreement. This Warrant (including any recitals hereto) and the Agreement set forth the entire understanding of the
Parties with respect to the subject matter hereof, and shall not be modified or affected by any offer, proposal, statement or
representation, oral or written, made by or for any Party in connection with the negotiation of the terms hereof, and may be
modified only by instruments signed by the Company and the Holder.

 

(d)
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next
succeeding Business Day.

 

    	 	9	 

    	 

    

 

(e)
Notices. All notices under this Warrant shall be in writing. Notices may be served by certified or registered mail, postage
paid with return receipt requested; by private courier, prepaid; by other reliable form of electronic communication; or personally.
Mailed notices shall be deemed delivered five (5) days after mailing, properly addressed. Couriered notices shall be deemed delivered
on the date that the courier warrants that delivery will occur. Electronic communication notices shall be deemed delivered when
receipt is either confirmed by confirming transmission equipment or acknowledged by the addressee or its office. Personal delivery
shall be effective when accomplished. Any Party may change its address by giving notice, in writing, stating its new address,
to the other Party. Subject to the forgoing, notices shall be sent as follows:

 

If
to the Company:

 

Nutralife
Biosciences, Inc.

Attn: Edgar Ward

6601
Lyons Road, Suite L-6

Coconut Creek, FL 33073

Email:
edgar@nutralifebiosciences.com

 

If
to Holder, to the address of Holder as set forth in the Agreement.

 

(f)
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities
laws.

 

(g)
No Waiver. No waiver of any provision of this Warrant shall be effective unless it is in writing and signed by the Party
against whom it is asserted, and any such written waiver shall only be applicable to the specific instance to which it relates
and shall not be deemed to be a continuing or future waiver.

 

(h)
Headings. The article and section headings contained in this Warrant are inserted for convenience only and shall not affect
in any way the meaning or interpretation of the Warrant.

 

(i)
Governing Law. This Warrant, and any dispute arising out of, relating to, or in connection with this Warrant, shall be
governed by and construed in accordance with the laws of the State of Florida, without giving effect to any choice or conflict
of law provision or rule (whether of the State of Florida or of any other jurisdiction) that would cause the application of the
laws of any jurisdiction other than the State of Florida.

 

    	 	10	 

    	 

    

 

(j)
Enforcement of the Warrant; Jurisdiction; No Jury Trial.

 

	 	(i)	Each
    of the Parties irrevocably agrees that any legal action or proceeding with respect to this Warrant and the rights and obligations
    arising under this Warrant, or for recognition and enforcement of any judgment or arbitral award or resolution in respect
    of this Warrant, shall be brought and determined exclusively in the courts of the State of Florida located in Broward County,
    Florida or in the event (but only in the event) that such courts do not have subject matter jurisdiction over such action
    or proceeding, in the United States District Court sitting in Broward County, Florida (the “Selected Courts”).
    Each of the Parties hereby irrevocably submits with regard to any such action or proceeding for itself and in respect of its
    property, generally and unconditionally, to the personal jurisdiction of the Selected Courts and agrees that it will not bring
    any action relating to this Warrant or any of the transactions contemplated by this Warrant in any court other than the Selected
    Courts. Each of the Parties hereby irrevocably waives, and agrees not to assert, by way of motion, as a defense, counterclaim
    or otherwise, in any action or proceeding with respect to this Warrant, (a) any claim that it is not personally subject to
    the jurisdiction of the Selected Courts for any reason other than the failure to serve in accordance with the provisions of
    this Warrant; (b) any claim that it or its property is exempt or immune from jurisdiction of any such court or from any legal
    process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution
    of judgment, execution of judgment or otherwise); and (c) to the fullest extent permitted by law, any claim that (i) the suit,
    action or proceeding in such court is brought in an inconvenient forum; (ii) the venue of such suit, action or proceeding
    is improper; or (iii) this Warrant, or the subject matter of this Warrant, may not be enforced in or by the Selected Courts.
	 	 	 
	 	(ii)	EACH
    PARTY TO THIS WARRANT HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT SUCH
    PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY SUIT, ACTION OR OTHER PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF,
    UNDER, RELATING TO OR IN CONNECTION WITH THIS WARRANT, OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT.
	 	 	 
	 	(iii)	The
    Holder hereby expressly acknowledges that the agreements and restrictions contained herein are reasonable and necessary to
    protect the Company’s legitimate interests, that the Company would not have entered into this Warrant in the absence
    of such agreements and restrictions, and that any violation of such restrictions will result in irreparable harm to the Company.
    The Holder agrees that the Company shall be entitled to preliminary and permanent injunctive relief, without the necessity
    of proving actual damages, and specific performance of, as well as an equitable accounting of all earnings, profits and other
    benefits arising from any violation of, the agreements and restrictions contained herein, which rights shall be cumulative
    and in addition to any other rights or remedies to which the Company may be entitled. The Holder irrevocably and unconditionally
    (i) agrees that any legal proceeding arising out of this Warrant may be brought in the Selected Courts, (ii) consents to the
    non-exclusive jurisdiction of the Selected Courts in any such proceeding, and (iii) waives any objection to the laying of
    venue of any such proceeding in any Selected Court.

 

    	 	11	 

    	 

    

 

(k)
Attorneys’ Fees. If any Party hereto is required to engage in litigation against any other Party, either as plaintiff
or as defendant, in order to enforce or defend any rights under this Warrant, and such litigation results in a final judgment
in favor of such Party (“Prevailing Party”), then the party or parties against whom said final judgment is obtained
shall reimburse the Prevailing Party for all direct, indirect or incidental expenses incurred, including, but not limited to,
all attorneys’ fees, court costs and other expenses incurred throughout all negotiations, trials or appeals undertaken in
order to enforce the Prevailing Party’s rights hereunder.

 

(l)
Parties in Interest. This Warrant shall be binding upon and inure solely to the benefit of each Party, and nothing in this
Warrant, express or implied, is intended to confer upon any other person or entity any rights or remedies of any nature under
or by reason of this Warrant.

 

(m)
Severability; Expenses; Further Assurances. If any term, condition or other provision of this Warrant is determined by
a court of competent jurisdiction to be invalid, illegal or incapable of being enforced by any rule of law or public policy, all
other terms, conditions and provisions of this Warrant shall nevertheless remain in full force and effect so long as the economic
or legal substance of the transactions contemplated by this Warrant is not affected in any manner materially adverse to any Party.
Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall
negotiate in good faith to modify this Warrant so as to effect the original intent of the Parties as closely as possible in a
mutually acceptable manner in order that the transactions contemplated by this Warrant be consummated as originally contemplated
to the fullest extent possible. Except as otherwise specifically provided in this Warrant, each Party shall be responsible for
the expenses it may incur in connection with the negotiation, preparation, execution, delivery, performance and enforcement of
this Warrant. The Parties shall from time to time do and perform any additional acts and execute and deliver any additional documents
and instruments that may be required by Law or reasonably requested by any Party to establish, maintain or protect its rights
and remedies under, or to effect the intents and purposes of, this Warrant.

 

(n)
Execution in Counterparts, Electronic Transmission. This Warrant may be executed in any number of counterparts, each of
which shall be deemed an original. The signature of any Party which is transmitted by any reliable electronic means such as, but
not limited to, a photocopy, electronically scanned or facsimile machine, for purposes hereof, is to be considered as an original
signature, and the document transmitted is to be considered to have the same binding effect as an original signature or an original
document.

 

(o)
No Assignment. This Warrant may not be assigned by either Party without the prior written consent of the other Party in
its sole discretion.

 

(p)
Currency. All dollar amounts are in U.S. dollars.

 

********************

 

(SIGNATURE PAGE FOLLOWS)

 

    	 	12	 

    	 

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the Issue Date.

 

	 	Nutralife Biosciences, Inc.
	 	 	 
	 	By:	/s/
    Edgar Ward
	 	Name:	Edgar
    Ward
	 	Title:	Chief
    Executive Officer

 

Agreed
and accepted: 

 

Gregory Ross

 

	By:	/s/
    Gregory Ross	 
	Name: 	Gregory Ross	 

 

    	 	13	 

    	 

    

 

NOTICE
OF EXERCISE

 

TO:
Nutralife Biosciences, Inc.

 

(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached
Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable
transfer taxes, if any.

 

(2)
Payment shall take the form of (check applicable box):

 

[  ]
in lawful money of the United States; or

 

[  ]
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in Section
2(c) of the attached Warrant, to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant
to the cashless exercise procedure set forth in such in Section 2(c).

 

(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

 

 

The
Warrant Shares shall be delivered to the following DWAC Account Number:

 

 

 

 

 

 

 

	Name
    of Holder:	 	 
	By:	 	 
	Name:	 	 
	Title:	 	 
	 	 	 
	Date:	__________________, 202   	 

 

    	 	14Exhibit
10.29

 

NUTRALIFE
BIOSCIENCES, INC. 

INVESTMENT
AGREEMENT

 

This
Investment Agreement (the “Investment Agreement”) is made and effective as of the day set forth on the signature page
hereto by and between NutraLife BioSciences, Inc., a Florida corporation (“NutraLife”), PhytoChem Technologies, Inc.
(“PhytoChem”), a Florida corporation (NutraLife and PhytoChem are collectively referred to herein as the “Company”),
and Kahn Family Limited PT II (the “Purchaser”). The Company and the Purchaser are referred to herein collectively
as the “Parties”, or individually as a “Party”.

 

RECITALS

 

WHEREAS,
the Company obtained certain rights to commercialize and monetize certain technology and phytoextractor equipment known as
the Ennea Processor (“Ennea” or “Ennea Processor”) pursuant to an agreement by and between Owen J. Morgan
(“Morgan”) and the Company dated February 4, 2019 (the “Morgan Agreement”.

 

WHEREAS,
the Ennea Processor uses certain technologies to separate, process and/or extract bioactive compounds including cannabinoids
from hemp and other plants to remove and/or modify, purify, dilute and extract bioactive ingredients and/or remove unwanted substances
to produce finished products for a variety of applications as more fully described on Exhibit A hereto;

 

WHEREAS,
the Company requires capital to manufacture, purchase, monetize and/or commercialize the Ennea;

 

WHEREAS,
the Company desires to issue and sell, and the Purchaser desires to purchase a full recourse secured convertible promissory
note attached hereto as Exhibit B (the “Note”) bearing interest at the rate of eight and one half percent (8.5%)
per annuum (the “Interest”) in the principal amount of $1,000,000 (“Principal” or the “Principal
Amount”) and the Company intends to use the Note proceeds to manufacture, purchase, monetize and/or commercialize the Ennea
Processors;.

 

WHEREAS,
the first four of the Ennea Processors (“Collateral Processors”) that the Company monetizes and/or commercializes
pursuant to the Morgan Agreement shall serve as collateral for the Principal Amount pursuant to the terms of the Security Agreement
(the “Security Agreement”) attached hereto as Exhibit C;

 

WHEREAS,
at any time while the Note is outstanding, the Purchaser shall have the right to convert the Note into shares of the Company’s
Common Stock at the price of $1.00 per share (the “Conversion Shares”);

 

WHEREAS,
as consideration for the purchase of the Note, the Company shall (i) pay to the Purchaser the Interest as set forth in the
Note, (ii) issue to the Purchaser, 500,000 shares of its Common Stock, $.0001 par value per share (the “Common Shares”),
and (iii) grant the Purchaser eight and one half percent (8.5%) of the revenue generated from the Collateral Processors (the “Royalty”)
while the Principal Amount is outstanding and five percent (5%) thereafter as set forth in the Royalty Agreement (the “Purchaser
Royalty Agreement”) attached hereto as Exhibit D;

 

WHEREAS,
the Principal Amount shall be secured by a mortgage on certain real property (the “Mortgage”) attached hereto
as Exhibit E pledged by a third party the (“Pledgor”) and such Mortgage shall be reduced by any and all consideration
of any nature that is paid by the Company to the Purchaser under the Transaction Documents (as defined herein); and

 

    	 	 	 

    	 

    

 

WHEREAS,
The Company shall pay the Pledgor certain consideration for the pledge of the Collateral pursuant to the terms of the Pledge
Agreement attached as Exhibit F (the “Pledge Agreement”).

 

NOW
THEREFORE, in consideration of the mutual promises contained herein and other good and valuable consideration, receipt of
which is hereby acknowledged, the parties to this Investment Agreement agree as follows:

 

ARTICLE
1. RECITALS.

 

ARTICLE
1.1 RECITALS. The above recitals are true and correct and made a part hereof.

 

ARTICLE
2. DEFINITIONS.

 

ARTICLE
2.1 SECURITIES. The Note, the Common Shares and the Conversion Shares are collectively referred to herein as the “Securities.”

 

ARTICLE
2.2 CAPITALIZED TERMS. The Note, Security Agreement, Purchaser Royalty Agreement, Pledge Agreement, Mortgage and Pledgor Royalty
Agreement are referred to as the “Ancillary Agreements.” This Investment Agreement and the Ancillary Agreements shall
be referred to collectively as the “Transaction Documents.”

 

Any
capitalized term not defined herein shall have the meaning ascribed to it in Transaction Documents.

 

ARTICLE
3. CONSIDERATION PAID TO THE PURCHASER.

 

ARTICLE
3.1 ADDITIONAL CONSIDERATION. In addition to the Company’s repayment of the Principal Amount and the payment of Interest
to the Company as set forth in the Note, the Company shall pay the following additional consideration to the Purchaser: (i) 500,000
of the Company’s Common Shares upon execution hereof, and (ii) the Royalty pursuant to the terms and conditions set forth
in the Purchaser Royalty Agreement.

 

ARTICLE
3.2 SECURITIES CONSIDERATION. The Common Shares upon issuance to the Purchaser will be duly authorized and, when issued and
paid for in accordance with this Investment Agreement and the Transaction Documents, will be duly and validly issued, fully paid
and nonassessable, free and clear of all liens. The Company has reserved from its duly authorized capital stock the maximum number
of shares of its common stock issuable upon the conversion of the Note.

 

ARTICLE
4. PURCHASE AND SALE OF THE NOTE.

 

ARTICLE
4.1 CLOSING. Subject to the terms and conditions of this Investment Agreement and the Note, the Purchaser agrees to purchase
at the Closing (as defined in 4.2 below) and the Company agrees to sell and issue to the Purchaser, the Note in the Principal
Amount.

 

ARTICLE
4.2 PLACE & TIME FOR CLOSING. The purchase and sale of the Note shall take place at the offices of the Company set forth
on the signature page hereto on June 6, 2019, or at such other time and place as the Company and the Purchaser mutually agree
upon orally or in writing (which time and place are designated as the “Closing”).

 

    	 	 	 

    	 

    

 

ARTICLE
4.3 CLOSING DELIVERIES. At the Closing, the Company shall deliver to the Purchaser signed copies of this Investment Agreement,
the Common Shares and the Ancillary Agreements duly executed according to their terms. At the Closing, the Purchaser shall deliver
to the Company funds representing the Principal Amount and signed copies of this Investment Agreement and the Ancillary Agreements
duly executed according to their terms.

 

ARTICLE
5. SECURITY & COLLATERAL.

 

ARTICL
5.1 THE COLLATERAL PROCESSORS AS SECURITY. The Principal Amount shall be secured by the Collateral Processors in accordance
with the provisions of the Note and Security Agreement.

 

ARTICLE
5.2 REAL PROPERTY. The Principal Amount shall be further secured by certain real property under the terms of the Pledge Agreement
and Mortgage and such Mortgage shall be reduced by any and all by all consideration of any nature that is paid to the Purchaser
by the Company under the Transaction Documents.

 

ARTICLE
6. REPRESENTATIONS AND WARRANTIES OF THE PARTIES.

 

ARTICLE
6.1 COMPANY REPRESENTATIONS. The Company hereby represents and warrants to the Purchaser that:

 

(i)
ORGANIZATION, GOOD STANDING AND QUALIFICATION. The Company is a corporation duly organized, validly existing and in good standing
under the laws of the State of Florida and has all requisite corporate power and authority to carry on its business as now conducted
and as proposed to be conducted (the “Business”). The Company is duly qualified to transact business
and is in good standing in each jurisdiction in which the failure so to qualify would have a material adverse effect on its business
or properties.

 

(ii)
AUTHORIZATION. All corporate action required on the part of the Company, its officers, directors, and stockholders necessary
for the authorization, execution, and delivery of this Investment Agreement and the Ancillary Agreements and the authorization,
sale, issuance, and delivery of this Investment Agreement and the Ancillary Agreements and the performance of all obligations
of the Company hereunder and under the Ancillary Agreements has been taken or will be taken prior to the Closing. This Investment
Agreement, and each of the Ancillary Agreements, when executed and delivered, shall constitute valid and legally binding agreements,
enforceable in accordance with their respective terms except as limited by applicable bankruptcy, insolvency, reorganization,
moratorium, fraudulent conveyance, and other laws of general application affecting enforcement of creditors’ rights generally,
and as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.

 

(iii)
ISSUANCE OF THE SECURITIES. The Securities upon issuance to the Purchaser will be duly authorized and, when issued and paid
for in accordance with this Investment Agreement and the Ancillary Agreements, will be duly and validly issued, fully paid and
nonassessable, free and clear of all liens. The Company has reserved from its duly authorized capital stock the maximum number
of shares of its common stock issuable upon the conversion of the Note.

 

    	 	 	 

    	 

    

 

ARTICLE
6.2 REPRESENTATIONS AND WARRANTIES OF THE PURCHASER. The Purchaser hereby represents and warrants to the Company that:

 

(i)
AUTHORIZATION. The Purchaser has full power and authority to enter into this Investment Agreement. This Investment Agreement,
when executed and delivered by the Purchaser, will constitute a valid and legally binding obligation of the Purchaser, enforceable
in accordance with its terms, except as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance,
and any other laws of general application affecting enforcement of creditors’ rights generally, and as limited by laws relating
to the availability of a specific performance, injunctive relief, or other equitable remedies.

 

(ii)
PURCHASE ENTIRELY FOR OWN ACCOUNT. This Investment Agreement is made with the Purchaser in reliance upon the Purchaser’s
representation to the Company, which by the Purchaser’s execution of this Investment Agreement, the Purchaser hereby confirms,
that the Securities to be acquired by the Purchaser will be acquired for investment for the Purchaser’s own account, not
as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that the Purchaser has no present
intention of selling, granting any participation in, or otherwise distributing the same. By executing this Investment Agreement,
the Purchaser further represents that the Purchaser does not presently have any contract, undertaking, agreement or arrangement
with any person to sell, transfer or grant participations to such person or to any third person, with respect to any of the Securities.

 

(iii)
KNOWLEDGE. The Purchaser is aware of the Company’s business affairs and financial condition and has acquired sufficient
information about the Company to reach an informed and knowledgeable decision to acquire the Securities.

 

(iv)
RESTRICTED SECURITIES. The Purchaser understands that the Securities have not been, and will not be, registered under the
Securities Act of 1933, as amended (the “Securities Act”), by reason of a specific exemption from the
registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent
and the accuracy of the Purchaser’s representations as expressed herein. The Purchaser understands that the Securities are
“restricted securities” under applicable U.S. federal and state securities laws and that, pursuant to these laws,
the Purchaser must hold the Securities indefinitely unless they are registered with the Securities and Exchange Commission and
qualified by state authorities, or an exemption from such registration and qualification requirements is available. The Purchaser
acknowledges that the Company has no obligation to register or qualify the Securities for resale. The Purchaser further acknowledges
that if an exemption from registration or qualification is available, it may be conditioned on various requirements including,
but not limited to, the time and manner of sale, the holding period for the Securities, and on requirements relating to the Company
which are outside of the Purchaser’s control, and which the Company is under no obligation and may not be able to satisfy.

 

(v)
LEGENDS. The Purchaser understands that the Securities may bear one or all of the following legends:

 

“THE
SECURITIES REPRESENTED BY THIS CERTIFICATE OR INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AND HAVE BEEN
ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION
MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY
TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.”

 

    	 	 	 

    	 

    

 

(v)
ACCREDITED INVESTOR. The Purchaser is an Accredited Investor as defined in Rule 501(a) of Regulation D promulgated under the
Securities Act.

 

ARTICLE
7. CONDITIONS TO CLOSING.

 

ARTICLE
7.1 OBLIGATION TO EXECUTE ANCILLARY AGREEMENTS. The obligations of the Purchaser and the Company under this Investment Agreement
are subject to the execution of the Ancillary Agreements by the parties thereto at or prior to the Closing.

 

ARTICLE
8. MISCELLANEOUS.

 

ARTICLE
8.1 ASSIGNMENT; SUCCESSORS AND ASSIGNS. The terms and conditions of this Investment Agreement shall inure to the benefit of
and be binding upon the respective successors and assigns of the Parties.

 

ARTICLE
8.2 WAIVER OF CONFLICTS. The Company and the Purchaser each acknowledge that the Pledgor, Brenda Hamilton and her law firm,
Hamilton & Associates Law Group, P.A has in the past performed, and may continue to perform, legal and/or consulting services
for the Company in connection with the Transaction Documents and the matters and transactions described in this Investment Agreement
as well as in matters unrelated to the Transaction Documents. Accordingly, the Company and Purchaser each hereby acknowledges
that they have been advised by Brenda Hamilton & Hamilton & Associates Law Group, P.A. to seek the advice of independent
legal counsel in connection with the Transaction Documents including with respect to the Pledge Agreement, Mortgage and Pledgor
Royal Agreement in which Brenda Hamilton is a Party and the transactions contemplated thereby. Additionally, the Company and Purchaser
each acknowledge that they have had an opportunity to ask for information relevant to this disclosure and has consulted with independent
legal counsel or has had the opportunity to do so and gives its informed consent to Brenda Hamilton & Hamilton & Associates
Law Group, P.A. representation of and/or performance of services for the Company in the connection with the Transaction Documents
and transactions contemplated thereby.

 

ARTICLE
8.3 GOVERNING LAW AND JURISDICTION. This Investment Agreement shall be governed by and construed in accordance with the laws
of the State of Florida without regard to principles of conflict law applicable to contracts made and to be performed with such
state. Each of the parties hereto accepts for itself to the jurisdiction of Palm Beach County Florida and irrevocably consents
to such jurisdiction in any proceedings and waives any objection to venue laid therein. Any controversy or claim arising out of
or relating of this Investment Agreement shall be settled by binding arbitration administered by the American Arbitration Association
and judgment on the award entered in any court having jurisdiction. The arbitration proceedings shall be conducted before a panel
of three neutral arbitrators in Palm Beach County, Florida all of whom shall be members of the bar of the state of Florida, actively
engaged in the practice of law for at least ten (10) years. Either Party hereto may apply to the arbitrator seeking injunctive
relief until the arbitration award is rendered or the controversy otherwise resolved. Either Party may, without waiving any remedy
under this Investment Agreement, seek from any court having jurisdiction any interim or provisional relief that is necessary to
protect the rights or property of that party, pending the arbitral tribunal’s determination of the merits of the controversy.
Each party shall bear its own costs, expenses and attorney fees and an equal share of the arbitrators’ and administrative
fees of arbitration. Except as may be required by law, neither a party nor an arbitrator may disclose the existence content or
results of any arbitration hereunder without the prior written consent of the Parties. All documents, testimony and records shall
be received, heard and maintained by the arbitrators in secrecy, available for the inspection only of the Parties to this Investment
Agreement and their respective attorneys and their respective experts who shall agree in advance and in writing to receive all
such information confidentially and to maintain such information in secrecy until such information shall become generally known.
In consideration for and as a material condition of this Investment Agreement, each Party agrees that final and binding arbitration
is the exclusive means for resolving any claim or controversy arising out of or related to this Investment Agreement. This Investment
Agreement is a waiver of all rights the Parties may have to a civil court action. Accordingly, only an arbitrator, not a judge
or jury, will decide the dispute, although the arbitrator has the authority to award any type of relief that could otherwise be
awarded by a judge or jury.

 

    	 	 	 

    	 

    

 

ARTICLE
8.4 COUNTERPARTS. This Investment Agreement may be executed
in counterparts, each of which is deemed an original, but all of which together are deemed to be one and the same agreement. A
signed copy of this Investment Agreement delivered by facsimile, e-mail or other means of electronic transmission is deemed to
have the same legal effect as delivery of an original signed copy of this Investment Agreement, if the Party sending such facsimile,
e-mail or other means of electronic transmission has received express confirmation that the recipient Party received the Investment
Agreement, not merely an electronic facsimile confirmation or automatic e-mail reply.

 

ARTICLE
8.5 TITLES AND SUBTITLES. The titles and subtitles used in this Investment Agreement are used for convenience only and are
not to be considered in construing or interpreting this Investment Agreement.

 

ARTICLE
8.6 FORCE MAJEURE. The Company shall not be liable or responsible to Purchaser, nor
be deemed to have defaulted under or breached this Investment Agreement, for any failure or delay in fulfilling or performing
any term of this Investment Agreement, if such failure or delay is caused by or results from acts beyond the Company’s control,
including: (i) acts of nature; (ii) flood,
fire, hurricane, earthquake or explosion; (iii) war, invasion, hostilities (whether
war is declared or not), terrorist threats or acts, riot or other civil unrest; (iv) actions,
embargos or blockades in effect on or after the date of this Investment Agreement; (v) national
or regional emergency; (vi) strikes, labor stoppages or slowdowns or other industrial
disturbances; (vii) shortages of or delays in receiving raw materials; or (viii)
shortage of adequate power or transportation facilities (each,
a “Force Majeure Event”).

 

ARTICLE
8.7 NOTICES. Any notice required or permitted by this Investment Agreement shall be in writing and shall be deemed sufficient
upon receipt, when delivered personally or by courier, overnight delivery service or confirmed facsimile, or 48 hours after being
deposited in the U.S. mail as certified or registered mail with postage prepaid, if such notice is addressed to the Party to be
notified at such Party’s address or facsimile number as set forth on the signature page hereto or as subsequently modified
by written notice.

 

ARTICLE
8.8 AMENDMENTS AND WAIVERS. Any term of this Investment Agreement may only be amended or waived with the written consent of
the Company and the Purchaser.

 

ARTICLE
8.9 SEVERABILITY. If one or more provisions of this Investment Agreement are held to be unenforceable under applicable law,
the parties agree to renegotiate such provision in good faith, in order to maintain the economic position enjoyed by each party
as close as possible to that under the provision rendered unenforceable. In the event that the parties cannot reach a mutually
agreeable and enforceable replacement for such provision, then (i) such provision shall be excluded from this Investment Agreement,
(ii) the balance of the Investment Agreement shall be interpreted as if such provision were so excluded and (iii) the balance
of the Investment Agreement shall be enforceable in accordance with its terms.

 

    	 	 	 

    	 	 	 

    

 

IN
WITNESS WHEREOF, the Parties hereto have executed this Investment Agreement on June 6, 2019.

 

	NUTRALIFE
    BIOSCIENCES, INC.	 	KAHN
    FAMILY LIMITED PT II
	 	 	 	 	 
	By:	 	 	By:	 
	 	Edgar
    Ward, Chief Executive Officer	 	 	(Signature)
	 	 	 	 	 
	PHYTOCHEM
    TECHNOLOGIES, INC.	 	 	(Print
    Name)
	 	 	 	 
	By:	 	 	 	 
	 	Edgar
    Ward, Chief Executive Officer	 	 	(Print
    Title)
	 	 	 	 
	 	Address
    for Notice:	 	 	Address
    for Notice:
	 	NutraLife
    Biosciences, Inc.	 	 	_________________________________
	 	Attn:
    Edgar Ward, Chief Executive Officer	 	 	_________________________________
	 	6601
    Lyons Rd. L-6 	 	 	_________________________________
	 	Coconut
    Creek, Fl. 33073	 	 	Phone:
    _________________________________
	 	edgar@NutraFuels.com	 	 	Email:
    _________________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}]]